Cargando…

Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance

Trastuzumab, a targeted anti-human epidermal-growth-factor receptor-2 (HER2) monoclonal antibody, represents a mainstay in the treatment of HER2-positive (HER2(+)) breast cancer. Although trastuzumab treatment is highly efficacious for early-stage HER2(+) breast cancer, the majority of advanced-stag...

Descripción completa

Detalles Bibliográficos
Autores principales:	Upton, Rosalynd, Banuelos, Allison, Feng, Dongdong, Biswas, Tanuka, Kao, Kevin, McKenna, Kelly, Willingham, Stephen, Ho, Po Yi, Rosental, Benyamin, Tal, Michal Caspi, Raveh, Tal, Volkmer, Jens-Peter, Pegram, Mark D., Weissman, Irving L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	National Academy of Sciences 2021
Materias:	Biological Sciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307693/ https://www.ncbi.nlm.nih.gov/pubmed/34257155 http://dx.doi.org/10.1073/pnas.2026849118

Ejemplares similares

Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies
por: Chao, Mark P., et al.
Publicado: (2020)

Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT)
por: Sella, Tal, et al.
Publicado: (2022)

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
por: Canonici, Alexandra, et al.
Publicado: (2013)

Resistance to Trastuzumab
por: Vivekanandhan, Sneha, et al.
Publicado: (2022)

Trastuzumab-induced thrombocytopenia after eight cycles of trastuzumab treatment
por: Zhou, Qiong, et al.
Publicado: (2020)

XeNA: Capecitabine Plus Docetaxel, With or Without Trastuzumab, as Preoperative Therapy for Early Breast Cancer
por: Glück, Stefan, et al.
Publicado: (2008)

Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
por: Waller, Cornelius F., et al.
Publicado: (2021)

Botryllus schlosseri as a Unique Colonial Chordate Model for the Study and Modulation of Innate Immune Activity
por: Goldstein, Oron, et al.
Publicado: (2021)

Immune Effects of Trastuzumab
por: Nuti, Marianna, et al.
Publicado: (2011)

Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit
por: Triulzi, Tiziana, et al.
Publicado: (2018)

Immunotherapeutic Blockade of CD47 Inhibitory Signaling Enhances Innate and Adaptive Immune Responses to Viral Infection
por: Cham, Lamin B., et al.
Publicado: (2020)

Targeting Gastric Cancer with Trastuzumab: New Clinical Practice and Innovative Developments to Overcome Resistance
por: Roukos, Dimitrios H.
Publicado: (2009)

Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It
por: Luque-Cabal, María, et al.
Publicado: (2016)

MUC1 is a potential target to overcome trastuzumab resistance in breast cancer therapy
por: Hosseinzadeh, Aysooda, et al.
Publicado: (2022)

CD47 blockade reduces the pathologic features of experimental cerebral malaria and promotes survival of hosts with Plasmodium infection
por: Torrez Dulgeroff, Laughing Bear, et al.
Publicado: (2021)

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
por: Cheong, E. Von, et al.
Publicado: (2021)

NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab
por: Ganz, Patricia A., et al.
Publicado: (2021)

Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group
por: Mackey, J.R., et al.
Publicado: (2008)

Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab
por: Spanov, Baubek, et al.
Publicado: (2022)

Trastuzumab: a cardiologist’s perspective
por: Côté, Marc André
Publicado: (2008)

Target Points in Trastuzumab Resistance
por: Shojaei, Sahar, et al.
Publicado: (2012)

Psoriasis Induced by Trastuzumab (Herceptin®)
por: Kim, Dae Hun, et al.
Publicado: (2013)

Trastuzumab deruxtecan for breast cancer
Publicado: (2022)

Trastuzumab-Induced Interstitial Pneumonitis
por: Errisuriz, Kimberly, et al.
Publicado: (2023)

Trastuzumab and ECG Changes Dilemma
por: Alizadehasl, Azin, et al.
Publicado: (2023)

Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential
por: Liu, Jie, et al.
Publicado: (2015)

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance
por: Cretella, Daniele, et al.
Publicado: (2014)

Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma
por: Peiró, G, et al.
Publicado: (2014)

Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance
por: Mitani, Seiichiro, et al.
Publicado: (2020)

Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1)
por: Diessner, J, et al.
Publicado: (2014)

A Case of Trastuzumab-Associated Cardiomyopathy Presenting as an Acute Coronary Syndrome: Acute Trastuzumab Cardiotoxicity
por: Hidalgo, Sylvana, et al.
Publicado: (2013)

Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting
por: Prete, Salvatore Del, et al.
Publicado: (2020)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
por: Yang, Jiangping, et al.
Publicado: (2022)

PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study
por: Pegram, Mark D., et al.
Publicado: (2018)

Safety survey on infusion reaction and cardiac dysfunction when switching from reference trastuzumab (HERCEPTIN(®)) to biosimilar trastuzumab (Trastuzumab‑NK) in the treatment of HER2‑positive breast cancer
por: Abe, Tomoya, et al.
Publicado: (2023)

A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer
por: Betancur, Paola A., et al.
Publicado: (2017)

Shorter course of trastuzumab: Caveat emptor
por: Venniyoor, Ajit
Publicado: (2011)

Dilated cardiomyopathy following trastuzumab chemotherapy
por: Karmakar, Saurabh, et al.
Publicado: (2012)

Severe thrombocytopenia related to trastuzumab infusion
por: Mantzourani, Marina, et al.
Publicado: (2011)

Trastuzumab Cardiotoxicity in Patients with Breast Cancer
por: Freitas, Aguinaldo Figueiredo, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_efaqfhu0r5h5ts33lsvhokpt0b